Clinical management of osteoporosis in women with a history of breast carcinoma Journal Article


Authors: Van Poznak, C.; Sauter, N. P.
Article Title: Clinical management of osteoporosis in women with a history of breast carcinoma
Abstract: Osteoporosis is a skeletal disorder that is characterized by low bone mass and compromised bone strength. Fractures are the clinically important consequence of osteoporosis and result not only in disability but also in excess mortality. Women who have a history of breast carcinoma may represent a unique population for whom screening and treatment for osteoporosis should be modified. A review of the English literature was performed that included original, review, consensus, and statement articles that were identified through Medline or National Institutes of Health-related links. According to the literature, osteoporosis constitutes a major public health problem. Approximately 55% of the U.S. population a 50 years of age has low bone mass (osteopenia or osteoporosis). Annually, > 200,000 women in the U.S. are diagnosed with breast carcinoma. Due to the high prevalence rates of both low bone mass and breast carcinoma in women, these two diseases commonly coexist in the same individuals. Women with a history of breast carcinoma may be at increased risk of developing bone loss and fragility fractures as a consequence of antineoplastic therapies. The majority of women treated for early-stage breast carcinoma do not develop recurrences, as a result of recent advances in therapy. Ensuring the diagnosis, prevention, and treatment of long-term toxicities and comorbid conditions like osteoporosis in breast carcinoma survivors is a serious concern and is of increasing importance. In this article, the authors address the evaluation and treatment of osteoporosis in women who have a history of early-stage breast carcinoma. © 2005 American Cancer Society.
Keywords: cancer chemotherapy; cancer survival; osteolysis; clinical trial; review; doxorubicin; nonhuman; antineoplastic agents; united states; cancer adjuvant therapy; methotrexate; cancer staging; antineoplastic agent; cancer diagnosis; unindexed drug; aromatase inhibitor; bisphosphonic acid derivative; calcium; cyclophosphamide; hypercalcemia; kidney failure; breast neoplasms; gonadorelin; bone density; exemestane; goserelin; screening; vitamin d; public health; breast carcinoma; glucocorticoid; tamoxifen; medline; aging; hormonal therapy; letrozole; bone mass; osteoporosis; high risk population; anticonvulsive agent; anastrozole; postmenopause; health care organization; thiazide diuretic agent; fragility fracture; zoledronic acid; bone disease; raloxifene; conjugated estrogen; gestagen; osteopenia; pamidronic acid; clodronic acid; ibandronic acid; risedronic acid; selective estrogen receptor modulator; metabolic acidosis; calcium carbonate; bone strength; citrate calcium; etidronic acid; adjuvant breast carcinoma survivorship; bone diseases, metabolic; osteoporosis, postmenopausal
Journal Title: Cancer
Volume: 104
Issue: 3
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 2005-08-01
Start Page: 443
End Page: 456
Language: English
DOI: 10.1002/cncr.21201
PUBMED: 15968687
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 19" - "Export Date: 24 October 2012" - "CODEN: CANCA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Nicholas Sauter
    10 Sauter